An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants
Completed · Phase 1 · Has a placebo group
Conditions studied: Cystic Fibrosis
In brief
The purpose of this study is to evaluate the effect of Vanzacaftor (VNZ) on QTcF, as well as the pharmacokinetic (PK), safety, and tolerability of VNZ in healthy participants.
Key facts
- Study ID
- NCT05867147
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 56
- Starts
- 2023-04-26
- Expected to finish
- 2023-06-14
- Last updated by the study team
- 2023-07-14
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.
Where it is running
- Celerion - Tempe — Tempe, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.